Sava Healthcare Limited

Sava Healthcare Limited, established on 25 October 2004, is a public unlisted company headquartered in Wadhwan City, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U51397GJ2004PLC074963. As of the latest available data, Sava Healthcare has an authorized capital of ₹16.40 crore and a paid-up capital of ₹58.77 lakh. The company employs approximately 568 professionals. Sava Healthcare operates in the pharmaceutical sector, focusing on the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's website is www.savaglobal.com.

Sava Healthcare Limited operates a WHO-GMP and PIC/s approved manufacturing plant located in Surendranagar, Gujarat. This facility specializes in the production of nasal drug delivery platforms, including nasal sprays and dry powder inhalers. The plant is strategically situated approximately 2.5 hours from Ahmedabad, facilitating efficient distribution. Additionally, the company is in the process of establishing a USFDA-accredited plant near Indore, India, to further enhance its manufacturing capabilities.

The leadership team at Sava Healthcare Limited includes:

• Vishal Ramchandra Jadhav: Director
• Vinod Ramchandra Jadhav: Director
• Sonal Sisodia: Director
• Ulhas Rajaram Puranik: Additional Director
• Renu Prashant Anjanikar: Additional Director
• Sunil Kumar Bajaj: Additional Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

Sava Healthcare Limited has made significant strides in regulated markets, particularly in the United States. The company is in the process of establishing a USFDA-accredited manufacturing plant near Indore, India, aiming to enhance its presence in the U.S. market. While specific details regarding regulatory filings and approvals in the European Union, United Kingdom, and Australia are not readily available, the company's adherence to WHO-GMP and PIC/s standards suggests a commitment to meeting international regulatory requirements. The establishment of a USFDA-accredited facility indicates a proactive approach to gaining market access in these regions.

Sava Healthcare Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's international business division has a global presence across Canada, Ukraine, the CIS, Asia, and Africa, with both human and veterinary pharmaceuticals. While specific details regarding WHO prequalification are not provided, the company's adherence to international manufacturing standards positions it favorably for market access in these regions.

Sava Healthcare Limited demonstrates a diversified geographic strategy by establishing manufacturing facilities in key locations and expanding its presence across various international markets. The development of a USFDA-accredited plant near Indore, India, reflects a strategic move to penetrate the U.S. market. The company's global footprint across Canada, Ukraine, the CIS, Asia, and Africa indicates a balanced approach to mitigating concentration risk and capitalizing on growth opportunities in diverse regions.

Sava Healthcare Limited is in the process of establishing a USFDA-accredited manufacturing plant near Indore, India. This initiative aims to enhance the company's manufacturing capabilities and facilitate market access in the United States. Specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not readily available. However, the company's commitment to obtaining USFDA accreditation underscores its dedication to meeting stringent regulatory standards.

Sava Healthcare Limited's manufacturing facility in Surendranagar, Gujarat, is WHO-GMP and PIC/s approved, indicating compliance with international manufacturing standards. While specific details regarding EU GMP certificates and EDQM status are not provided, the company's adherence to WHO-GMP standards suggests a commitment to meeting European regulatory requirements.

Sava Healthcare Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's manufacturing facility in Surendranagar, Gujarat, is approved by WHO-GMP and PIC/s, reflecting adherence to international manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not readily available.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Sava Healthcare Limited. The company's adherence to WHO-GMP and PIC/s standards suggests a proactive approach to regulatory compliance.

Sava Healthcare Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as antimalarial and antiparasitic, cardiovascular, and respiratory products. While specific market share comparisons are not readily available, the company's focus on nasal drug delivery platforms and its global presence across Canada, Ukraine, the CIS, Asia, and Africa position it as a notable player in the market.

Sava Healthcare Limited's key differentiators include its specialization in nasal drug delivery platforms, such as nasal sprays and dry powder inhalers, and its adherence to international manufacturing standards like WHO-GMP and PIC/s. The company's global footprint across diverse regions and its commitment to establishing a USFDA-accredited manufacturing facility further distinguish it in the competitive landscape.

Sava Healthcare Limited's current strategic direction encompasses generics, specialty pharmaceuticals, and Contract Development and Manufacturing Organization (CDMO) services. The company's focus on nasal drug delivery platforms and its expansion into global markets reflect a commitment to innovation and growth. The establishment of a USFDA-accredited manufacturing facility near Indore, India, indicates a proactive approach to enhancing manufacturing capabilities and market access.

Sava Healthcare Limited demonstrates a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a global presence. The company's adherence to WHO-GMP and PIC/s standards, along with its plans to establish a USFDA-accredited manufacturing facility, underscore its commitment to quality and regulatory compliance. While specific export volumes and consistency metrics are not readily available, the company's strategic initiatives and global footprint suggest reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.
• PIC/s Certification: Demonstrates adherence to Pharmaceutical Inspection Co-operation Scheme standards.
• USFDA Accreditation: Confirms compliance with U.S. Food and Drug Administration regulations.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

When considering Sava Healthcare Limited as a supplier, importers should:

• Verify Certifications: Ensure the company holds valid WHO-GMP, PIC/s, and USFDA certifications.
• Assess Manufacturing Facilities: Evaluate the capabilities and compliance of the manufacturing plant in Surendranagar, Gujarat.
• Review Regulatory Compliance: Confirm adherence to CDSCO and international regulatory standards.
• Evaluate Financial Stability: Review the company's financial statements for insights into its economic health.
• Check References: Seek feedback from existing clients to gauge reliability and product quality.

Red flags to watch for include expired certifications, unresolved regulatory issues, and negative client feedback. Recommended pre-order checks involve obtaining product samples, verifying batch records, and conducting quality audits.